1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

FDA Readies ICH Q12 Implementation Guidance, Learns Lessons From Pilot

 
• By Joanne S. Eglovitch

Upcoming ICH Q12 implementation guidance will translate terminology on post-approval changes into a US context, said a US FDA official who also shared some lessons learned on established conditions.

Manufacturing Flow chart
US FDA About To Release ICH Q12 Implementation Guideline • Source: Shutterstock

The US Food and Drug Administration will soon be issuing guidance implementing the International Council on Harmonization’s Q12 guideline in the US that will, among other things, translate ICH post-approval change classification categories to FDA supplement categories, and address how to file established conditions, or ECs.

The FDA’s Mahesh Ramanadham provided an update on the agency’s implementation of ICH Q12 in the US on 25 February...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

Compounders Argue US FDA’s GLP-1 Green List Validates Legit Practices

 
• By Aakash Babu

The compounding industry said the FDA’s “green list” of GLP-1 API imports for compounded drugs validates legitimate compounding pharmacies’ role in the US health system.

New US FDA Program Encouraging Domestic Manufacturing May Be ‘Very Selective’

 
• By Sarah Karlin-Smith

Pharmaceutical manufacturers encouraged the FDA to consider including expansions and modifications of existing US drug facilities in the PreCheck program.

US Tariffs And Geopolitical Tensions Push EU To New Trade Routes And Infrastructure Growth

 
• By Francesca Bruce

The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.

Homework Avoidance: US FDA’s Upfront Effort For CMC Pilot Dissuades Participation

 
• By Bridget Silverman

The clarity on quality topics provided by the CMC Readiness Pilot (CDRP) is worth the work of preparing a comprehensive development review and multiple meetings, participants from Intellia, Bicycle Therapeutics and Bristol Myers Squibb said during a Duke Margolis meeting.

More from Compliance

Compounders Argue US FDA’s GLP-1 Green List Validates Legit Practices

 
• By Aakash Babu

The compounding industry said the FDA’s “green list” of GLP-1 API imports for compounded drugs validates legitimate compounding pharmacies’ role in the US health system.

FTC’s New Healthcare Division Chief Is Former Antitrust Prosecutor

 
• By Malcolm Spicer

Emma Mittelstaedt Burnham prosecuted antitrust violations in healthcare sector in her previous work at DoJ, including leading investigation into antitrust cartels in the generic pharmaceutical industry.

Under Trump, Antitrust Regulators May Be More Divestiture Friendly

 
• By Tim Casey

The Trump Administration may differ from the Biden Administration in some areas of health care antitrust enforcement, but experts said some Biden-era priorities may be maintained.